文献速递银屑病与炎症性皮肤病

eIF4E作为抗银屑病治疗靶点

Eukaryotic Initiation Factor 4E (eIF4E) as a Target of Anti-Psoriatic Treatment.
PubMed 文献 · J Invest Dermatol · 2023-10-20

本研究探索真核起始因子4E(eIF4E)在银屑病病理生理中的作用。用小干扰RNA或eIF4E小分子抑制剂briciclib抑制eIF4E,可下调eIF4E及其复合伙伴eIF4A、G和其他eIFs表达。该抑制在咪喹莫特和TGFβ小鼠模型及人三维银屑病组织模型中均消除了银屑病炎症,briciclib局部应用与细胞增殖、表皮增生、促炎细胞因子水平和角化细胞分化标志物正常化相关。

要点

  • 抑制eIF4E可下调eIF4E及eIF4A、G和其他eIFs表达。
  • eIF4E抑制在咪喹莫特和TGFβ小鼠模型及人三维银屑病组织模型中消除银屑病炎症。
  • briciclib局部应用与细胞增殖、表皮增生、促炎细胞因子和分化标志物正常化相关。

核心结论

  • 结果证明翻译失衡并强调eIF4E和其他eIFs在银屑病病理生理中的关键作用。
  • 本研究为靶向eIF4E开发新型局部抗银屑病治疗策略开辟了途径。

研究设计与样本

  • 研究探索eIF4E在银屑病病理生理中的作用,使用小干扰RNA或briciclib抑制eIF4E,并在咪喹莫特和TGFβ小鼠模型及人三维银屑病组织模型中验证。

主要发现

  • 抑制eIF4E下调eIF4E自身及其两个复合伙伴eIF4A和G,以及其他eIFs(如eIF1A、eIF2α、eIF3A、eIF3B、eIF5和eIF6)。
  • 抑制eIF4E在咪喹莫特和TGFβ小鼠模型及人三维银屑病组织模型中消除了银屑病炎症。
  • 应用briciclib(尤其局部给药)下调eIF4E和其他eIFs,与细胞增殖、表皮增生、促炎细胞因子(如TNFα、IL-1b、IL-17和IL-22)水平及角化细胞分化标志物(如KRT16和FLG)的正常化相关。

临床怎么用

  • 靶向eIF4E可能为开发新型局部抗银屑病治疗策略提供途径。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Eukaryotic initiation factor 4E (eIF4E) has been known to play a critical role in the regulation of gene expression and essential cellular processes, such as proliferation, apoptosis and differentiation. In this study, we explored its role in the pathophysiology of psoriasis. The inhibition of eIF4E by small interfering RNA or briciclib, an eIF4E small molecule inhibitor, downregulated the expression of eIF4E itself and its two complex partners eIF4A and G, as well as other eIFs (eg, eIF1A, eIF2α, eIF3A, eIF3B, eIF5, and eIF6). This inhibition also abolished psoriatic inflammation in both the imiquimod and TGFß mouse model, as well as in a human 3 dimensional-psoriasis tissue model. Downregulation of eIF4E and the other eIFs by application of briciclib (particularly when given topically) was linked to the normalization of cellular proliferation, epidermal hyperplasia, levels of proinflammatory cytokines (eg, TNFα, IL-1b, IL-17, and IL-22), and keratinocyte differentiation markers (eg, KRT16 and FLG). These results demonstrate translational imbalance and underline the crucial role played by eIF4E and other eIFs in the pathophysiology of psoriasis. This work opens up avenues for the development of novel topical antipsoriatic treatment strategies by targeting eIF4E.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Golob-Schwarzl N, Pilic J, Benezeder T, et al. Eukaryotic Initiation Factor 4E (eIF4E) as a Target of Anti-Psoriatic Treatment. J Invest Dermatol. 2023. PMID: 37865179. doi:10.1016/j.jid.2022.12.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。